Citadel Advisors’s CollPlant Biotechnologies OPHI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-5,370
Closed -$18.7K – 14111
2026
Q2
$18.7K Buy
5,370
+2,153
+67% +$8.3K ﹤0.01% 13418
2026
Q1
$17.2K Buy
+3,217
New +$32.5K ﹤0.01% 12700
2024
Q2
– Sell
-1,319
Closed -$71.1K – 14362
2024
Q1
$71.1K Buy
1,319
+646
+96% +$34.9K ﹤0.01% 11799
2023
Q4
$43K Buy
+673
New +$36.8K ﹤0.01% 11940
2021
Q3
– Sell
-1,303
Closed -$276K – 13859
2021
Q2
$276K Buy
+1,303
New +$208K ﹤0.01% 11461
2021
Q1
– Sell
-1,194
Closed -$126K – 13203
2020
Q4
$126K Buy
1,194
+97
+9% +$7.84K ﹤0.01% 10061
2020
Q3
$88K Buy
+1,097
New +$98.7K ﹤0.01% 9345
2019
Q3
– Sell
-1,112
Closed -$44K – 9206
2019
Q2
$44K Buy
+1,112
New +$58.4K ﹤0.01% 8761
2018
Q4
– Sell
-1,389
Closed -$72K – 9155
2018
Q3
$72K Buy
+1,389
New +$76.6K ﹤0.01% 8697

Other funds holding OPHI

Citadel Advisors's OPHI Position: Q3 2026 in Review

Citadel Advisors sold out of CollPlant Biotechnologies (OPHI) in Q3 2026, closing a stake of 5,370 shares — an estimated $18.7K sold.

Citadel Advisors first reported a position in OPHI in Q3 2018 and held it in 9 quarters. The position peaked at $276K in Q2 2021. 8 funds tracked by Wall St. Rank hold OPHI as of Q3 2026.

  • Citadel Advisors reported no remaining CollPlant Biotechnologies position as of Q3 2026 after selling out during the quarter.
  • Citadel Advisors sold 5,370 CollPlant Biotechnologies shares in Q3 2026, an estimated $18.7K.
  • Citadel Advisors first reported a position in CollPlant Biotechnologies in Q3 2018 and held it in 9 quarters.
  • Citadel Advisors's CollPlant Biotechnologies position peaked at $276K in Q2 2021.
  • 8 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.